1 terminated. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Terminated 1 |
Follow CPI-006: new trials by email Literature Review of CPI-006 trials Research Report on CPI-006
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients CPI-006 2 mg/kg + SOC, CPI-006 1 mg/kg + SOC, Placebo + SOC - Covid-19 | Phase 3 | Terminated | Corvus Pharmaceuticals, Inc. | 46 | 2021-02-25 | 2022-09-21 |
COVID-19 (1) · Coronavirus Infections (1)
Corvus Pharmaceuticals, Inc. (1)
Argentina (1) · Brazil (1) · Canada (1) · Chile (1) · Colombia (1) · Germany (1) · Italy (1) · Mexico (1) · Peru (1) · Spain (1) · Ukraine (1) · United States (1)